A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial

Inclusion Criteria

• •Patient who is planning to start standard-of-care AI therapy and receive treatment for at least 24 weeks. Can be planning to take AI therapy for stage 0-3 breast cancer or because they are at high risk of developing breast cancer. Concurrent gonadotropin-releasing hormone antagonist (GnRHa) therapy, anti-osteoclast therapy, anti-HER2 therapy, ribociclib, and/or PARP inhibitor are permitted
• •Average joint pain 0-6 on a 0-10 scale during the 7 days prior to study enrollment
• •Able to take oral medication
• •Able to read and understand English
• •Aware of the nature of her diagnosis, understands study requirement, and able to sign an informed consent form